PHASE 1/2, OPEN-LABEL, RANDOMIZED STUDY OF THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF LETROZOLE PLUS PD 0332991 (ORAL CDK 4/6 INHIBITOR) AND LETROZOLE SINGLE AGENT FOR THE FIRST-LINE TREATMENT OF ER POSITIVE, HER2 NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN
收藏DataCite Commons2025-06-01 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006832/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess
the effect of the combination on advanced breast cancer
提供机构：
Vivli
创建时间：
2021-04-02
